• LAST PRICE
    0.8938
  • TODAY'S CHANGE (%)
    Trending Up0.0327 (3.7975%)
  • Bid / Lots
    0.8860/ 1
  • Ask / Lots
    0.9036/ 1
  • Open / Previous Close
    0.8650 / 0.8611
  • Day Range
    Low 0.8650
    High 0.9100
  • 52 Week Range
    Low 0.3010
    High 2.5901
  • Volume
    16,692
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.8956
TimeVolumeMREO
09:32 ET45850.885
09:34 ET7030.91
09:38 ET107000.8655
09:39 ET2900.8938
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMREO
Mereo Biopharma Group PLC
96.3M
-0.1x
---
United StatesCSBR
Champions Oncology Inc
103.9M
309.4x
---
United StatesSLGL
Sol Gel Technologies Ltd
116.3M
13.8x
---
United StatesSTTK
Shattuck Labs Inc
110.2M
-1.9x
---
United StatesFIXX
Homology Medicines Inc
87.3M
-40.3x
---
United StatesIKNA
Ikena Oncology Inc
129.4M
-2.4x
---
As of 2022-10-03

Company Information

Mereo BioPharma Group plc is a United Kingdom-based biopharmaceutical company. The Company is focused on the development of therapeutics that aim to improve outcomes for oncology and rare diseases and focuses on commercializing selected rare disease programs. Its portfolio consists of six clinical-stage product candidates two of which, Etigilimab (MPH-313) and Alvelestat (MPH-966), are in ongoing clinical studies. Its lead oncology product candidate, MPH-313 is an anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antibody. Its second oncology product, Navicixizumab (OMP-305B83) is used for the treatment of late line ovarian cancer. Its rare disease product candidates are Alvelestat, is for the treatment of severe alpha-1 antitrypsin deficiency (AATD). Its Setrusumab (BPS-804) is an antibody designed to inhibit sclerostin, a protein that inhibits the activity of bone-forming cells. Its other product candidates include Acumapimod (BCT-197) and Leflutrozole (BGS-649).

Contact Information

Headquarters
Fourth Fl, 1 Cavendish PlaceLONDON, United Kingdom W1G 0QF
Phone
---
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Peter Fellner
Chief Executive Officer, Director
Denise Scots-Knight
Non-Executive Independent Deputy Chairman of the Board
Michael Wyzga
Chief Financial Officer
Christine Fox
Senior Vice President - Clinical Development
Suba Krishnan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$96.3M
Revenue (TTM)
$0.00
Shares Outstanding
117.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.79
EPS
$-6.22
Book Value
$0.80
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.